Petco Health + Wellness Company, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

26.03.25 21:02 Uhr

Expects Double-Digit Adjusted EBITDA Growth in 2025*

SAN DIEGO, March 26, 2025 /PRNewswire/ -- Petco Health and Wellness Company, Inc. (Nasdaq: WOOF) today announced its fourth quarter and full year 2024 financial results.

Petco Health + Wellness Company, Inc. Logo (PRNewsfoto/Petco Health and Wellness Company, Inc.)

Q4 2024 Overview

  • Net revenue of $1.6 billion decreased 7.3% year over year inclusive of the negative impact from the loss of the 53rd week in 2023
  • Comparable sales increased 0.5% year over year
  • Gross profit of $589.3 million decreased 2.8% year over year compared to $606.3 million last year
  • GAAP net loss of $13.8 million compared to GAAP net loss of $22.6 million last year
  • Adjusted EBITDA1 of $96.1 million compared to $105.3 million last year

Full Year 2024 Overview

  • Net revenue of $6.1 billion decreased 2.2% year over year inclusive of the negative impact from the loss of the 53rd week in 2023
  • Comparable sales increased 0.3% year over year
  • Gross profit of $2.3 billion decreased 1.3% year over year compared to $2.4 billion last year
  • GAAP net loss of $101.8 million compared to GAAP net loss of $1.3 billion last year inclusive of a $1.2 billion non-cash goodwill impairment charge
  • Adjusted EBITDA1 of $336.5 million compared to $401.1 million last year
  • Operating cash flow of $177.7 million compared to $215.7 million last year
  • Free Cash Flow1 of $49.7 million compared to ($9.9) million last year

"Our results in the fourth quarter demonstrate the progress we've made to return Petco to retail operating excellence," said Joel Anderson, Petco's Chief Executive Officer. "While there is more work ahead, I am confident our new leadership team is well-positioned to build on this early momentum, deliver double-digit adjusted EBITDA improvement in 2025 and set the business up for sustainable profitable growth."

Full Year 2025 Guidance


FY 2025 Guidance*

    Net revenue

Down low single digits year over year

    Adjusted EBITDA

$375 million to $390 million

    Net interest expense

~$130 million

    Capital expenditures

$130-140 million

    Depreciation & amortization 

~$200 million

    Real estate

~20-30 net closures

First Quarter 2025 Guidance


Q1 2025 Guidance*

    Net revenue

Down low single digits year over year

 Adjusted EBITDA 

$82 million to $83 million

*Assumptions in the guidance include that economic conditions, currency rates and the tax and regulatory landscape remain generally consistent. Adjusted EBITDA is a non-GAAP financial measure and has not been reconciled to the most comparable GAAP outlook because it is not possible to do so without unreasonable efforts due to the uncertainty and potential variability of reconciling items, which are dependent on future events and often outside of management's control and which could be significant. Because such items cannot be reasonably predicted with the level of precision required, we are unable to provide outlook for the comparable GAAP measures. Forward-looking estimates of Adjusted EBITDA are made in a manner consistent with the relevant definitions and assumptions noted herein and in our filings with the Securities and Exchange Commission.

(1)

Adjusted EBITDA and Free Cash Flow are non-GAAP financial measures. See "Non-GAAP Financial Measures" for additional information on non-GAAP financial measures and a reconciliation to the most comparable GAAP measures.

Earnings Conference Call Webcast Information:

Management will host an earnings conference call on March 26, 2025 at approximately 4:30 PM Eastern Time to discuss the company's financial results. The conference call will be accessible through a live webcast. Interested  investors and other individuals can access the webcast, earnings release, and earnings presentation via the company's investor relations page at ir.petco.com. A replay of the webcast will be archived on the company's investor relations page through April 9, 2025 until approximately 5:00 PM Eastern Time.

About Petco, The Health + Wellness Co.:  
Founded in 1965, Petco is a category-defining health and wellness company focused on improving the lives of pets, pet parents and our own Petco partners. We've consistently set new standards in pet care while delivering comprehensive pet wellness products, services and solutions, and creating communities that deepen the pet-pet parent bond. We operate more than 1,500 pet care centers across the U.S., Mexico and Puerto Rico, which offer merchandise, companion animals, grooming, training and a growing network of on-site veterinary hospitals and mobile veterinary clinics. Our complete pet health and wellness ecosystem is accessible through our pet care centers and digitally at petco.com and on the Petco app. In tandem with Petco Love, a life-changing independent nonprofit organization, we work with and support thousands of local animal welfare groups across the country and, through in-store adoption events, we've helped find homes for nearly 7 million animals.

Forward-Looking Statements:

This earnings release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, concerning expectations, beliefs, plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are not statements of historical fact, including, but not limited to, statements regarding our Q1 and full year 2025 guidance, operational reset of our business, our competitive positioning, profitability, cost action plans and associated cost-savings. Such forward-looking statements can generally be identified by the use of forward-looking terms such as "believes," "expects," "may," "intends," "will," "shall," "should," "anticipates," "opportunity," "illustrative," or the negative thereof or other variations thereon or comparable terminology. Although Petco believes that the expectations and assumptions reflected in these statements are reasonable, there can be no assurance that these expectations will prove to be correct or that any forward-looking results will occur or be realized. Nothing contained in this earnings release is, or should be relied upon as, a promise or representation or warranty as to any future matter, including any matter in respect of the operations or business or financial condition of Petco. All forward-looking statements are based on current expectations and assumptions about future events that may or may not be correct or necessarily take place and that are by their nature subject to significant uncertainties and contingencies, many of which are outside the control of Petco. Forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results or events to differ materially from the potential results or events discussed in the forward-looking statements, including, without limitation, those identified in this earnings release as well as the following: (i) increased competition (including from multi-channel retailers, mass and grocery retailers, and e-Commerce providers); (ii) reduced consumer demand for our products and/or services; (iii) our reliance on key vendors; (iv) our ability to attract and retain qualified employees; (v) risks arising from statutory, regulatory and/or legal developments; (vi) macroeconomic pressures in the markets in which we operate, including inflation, prevailing interest rates and the impact of tariffs; (vii) failure to effectively manage our costs; (viii) our reliance on our information technology systems; (ix) our ability to prevent or effectively respond to a data privacy or security breach; (x) our ability to effectively manage or integrate strategic ventures, alliances or acquisitions and realize the anticipated benefits of such transactions; (xi) economic or regulatory developments that might affect our ability to provide attractive promotional financing; (xii) business interruptions and other supply chain issues; (xiii) catastrophic events, political tensions, conflicts and wars (such as the ongoing conflicts in Ukraine and the Middle East), health crises, and pandemics; (xiv) our ability to maintain positive brand perception and recognition; (xv) product safety and quality concerns; (xvi) changes to labor or employment laws or regulations; (xvii) our ability to effectively manage our real estate portfolio; (xviii) constraints in the capital markets or our vendor credit terms; (xix) changes in our credit ratings; (xx) impairments of the carrying value of our goodwill and other intangible assets; (xxi) our ability to successfully implement our operational adjustments, achieve the expected benefits of our cost action plans and drive improved profitability; and (xxii) the other risks, uncertainties and other factors identified under "Risk Factors"  and elsewhere in Petco's Securities and Exchange Commission filings. The occurrence of any such factors could significantly alter the results set forth in these statements.

Petco cautions that the foregoing list of risks, uncertainties and other factors is not complete, and forward-looking statements speak only as of the date they are made. Petco undertakes no duty to update publicly any such forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by applicable law, regulation or other competent legal authority.

PETCO HEALTH AND WELLNESS COMPANY, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(Unaudited and subject to reclassification)
















13 Weeks
Ended


14 Weeks
Ended




52 Weeks
Ended


53 Weeks
Ended





February 1,
2025


February 3,
2024


Percent
Change


February 1,
2025


February 3,
2024


Percent
Change

Net sales:













Products


$     1,310,217


$     1,420,713


(8 %)


$     5,116,891


$     5,273,710


(3 %)

Services and other


241,913


253,763


(5 %)


999,571


981,574


2 %

Total net sales


1,552,130


1,674,476


(7 %)


6,116,462


6,255,284


(2 %)

Cost of sales:













Products


811,204


903,156


(10 %)


3,173,269


3,269,628


(3 %)

Services and other


151,666


164,972


(8 %)


618,791


631,821


(2 %)

Total cost of sales


962,870


1,068,128


(10 %)


3,792,060


3,901,449


(3 %)

Gross profit


589,260


606,348


(3 %)


2,324,402


2,353,835


(1 %)

Selling, general and administrative expenses


571,872


606,182


(6 %)


2,317,351


2,311,625


0 %

Goodwill impairment




N/M



1,222,524


(100 %)

Operating income (loss)


17,388


166


10,375 %


7,051


(1,180,314)


N/M

Interest income


(1,278)


(326)


292 %


(3,714)


(3,405)


9 %

Interest expense


34,111


39,658


(14 %)


143,531


150,909


(5 %)

Loss on extinguishment and modification of debt




N/M



920


(100 %)

Other non-operating loss (income)


1,000



N/M


(4,800)


(4,727)


2 %

Loss before income taxes and income from
   equity method investees


(16,445)


(39,166)


(58 %)


(127,966)


(1,324,011)


(90 %)

Income tax expense (benefit)


2,504


(10,435)


N/M


(7,481)


(27,613)


(73 %)

Income from equity method investees


(5,112)


(6,156)


(17 %)


(18,669)


(16,188)


15 %

Net loss attributable to Class A and B-1 common
   stockholders


$        (13,837)


$        (22,575)


(39 %)


$      (101,816)


$   (1,280,210)


(92 %)














Net loss per Class A and B-1 common share:













Basic


$            (0.05)


$            (0.08)


(40 %)


$            (0.37)


$            (4.78)


(92 %)

Diluted


$            (0.05)


$            (0.08)


(40 %)


$            (0.37)


$            (4.78)


(92 %)














Weighted average shares used in computing net loss per Class A
   and B-1 common share:













Basic


276,305


268,615


3 %


273,410


267,549


2 %

Diluted


276,305


268,615


3 %


273,410


267,549


2 %

 

PETCO HEALTH AND WELLNESS COMPANY, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except per share amounts)

(Unaudited and subject to reclassification)






 February 1,
2025 


 February 3,
2024 

ASSETS





Current assets:





Cash and cash equivalents


$        165,756


$        125,428

Receivables, less allowance for credit losses1


40,425


44,369

Merchandise inventories, net


653,329


684,502

Prepaid expenses


53,515


58,615

Other current assets


60,594


38,830

Total current assets


973,619


951,744

Fixed assets, net


725,438


816,367

Operating lease right-of-use assets


1,302,346


1,384,050

Goodwill


980,064


980,297

Trade name


1,025,000


1,025,000

Other long-term assets


187,963


205,694

Total assets


$     5,194,430


$     5,363,152

LIABILITIES AND EQUITY





Current liabilities:





Accounts payable and book overdrafts


$        492,878


$        485,131

Accrued salaries and employee benefits


157,460


101,265

Accrued expenses and other liabilities


177,079


200,278

Current portion of operating lease liabilities


306,400


310,507

Current portion of long-term debt and other lease liabilities


5,346


15,962

Total current liabilities


1,139,163


1,113,143

Senior secured credit facilities, net, excluding current portion


1,578,091


1,576,223

Operating lease liabilities, excluding current portion


1,037,206


1,116,615

Deferred taxes, net


217,712


251,629

Other long-term liabilities


108,628


121,113

Total liabilities


4,080,800


4,178,723

Commitments and contingencies





Stockholders' equity:





Class A common stock2


239


231

Class B-1 common stock3


38


38

Class B-2 common stock4



Preferred stock5



Additional paid-in-capital


2,280,495


2,229,582

Accumulated deficit


(1,149,059)


(1,047,243)

Accumulated other comprehensive (loss) income


(18,083)


1,821

Total stockholders' equity


1,113,630


1,184,429

Total liabilities and stockholders' equity


$      5,194,430


$     5,363,152


¹ Allowances for credit losses are $1,594 and $1,806, respectively

² Class A common stock, $0.001 par value: Authorized - 1.0 billion shares;
        Issued and outstanding - 239.1 million and 231.2 million shares, respectively

³ Class B-1 common stock, $0.001 par value: Authorized - 75.0 million shares;
        Issued and outstanding - 37.8 million shares

⁴ Class B-2 common stock, $0.000001 par value: Authorized - 75.0 million shares;
        Issued and outstanding - 37.8 million shares

⁵ Preferred stock, $0.001 par value: Authorized - 25.0 million shares;
        Issued and outstanding - none

 

PETCO HEALTH AND WELLNESS COMPANY, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited and subject to reclassification)








52 Weeks
Ended


53 Weeks
Ended



February 1,
2025


February 3,
2024

Cash flows from operating activities:





Net loss


$   (101,816)


$ (1,280,210)

Adjustments to reconcile net loss to net cash provided by
  operating activities:





Depreciation and amortization


199,727


200,782

Amortization of debt discounts and issuance costs


4,896


4,972

Provision for deferred taxes


(30,492)


(53,549)

Equity-based compensation expense


50,212


81,859

Impairments, write-offs and losses on sale of fixed and other assets


8,790


2,833

Loss on extinguishment and modification of debt



920

Income from equity method investees


(18,669)


(16,188)

Amounts reclassified out of accumulated other comprehensive loss


(3,146)


(488)

Goodwill impairment



1,222,524

Non-cash operating lease costs


414,396


429,056

Other non-operating loss (income)


(4,800)


(4,727)

Changes in assets and liabilities:





Receivables


4,178


5,211

Merchandise inventories


30,767


(32,072)

Prepaid expenses and other assets


(3,960)


(8,009)

Accounts payable and book overdrafts


8,484


103,919

Accrued salaries and employee benefits


56,981


11,347

Accrued expenses and other liabilities


(12,455)


(8,495)

Operating lease liabilities


(418,219)


(446,981)

Other long-term liabilities


(7,201)


3,015

      Net cash provided by operating activities


177,673


215,719

Cash flows from investing activities:





Cash paid for fixed assets


(127,990)


(225,598)

Cash paid for acquisitions, net of cash acquired


(629)


(6,725)

Cash paid for investments


(457)


Proceeds from investment


998


24,878

Proceeds from sale of assets


1,369


Cash received from partial surrender of officers' life insurance


2,806


      Net cash used in investing activities


(123,903)


(207,445)

Cash flows from financing activities:





Borrowings under long-term debt agreements


201,000


273,000

Repayments of long-term debt


(201,000)


(348,000)

Debt refinancing costs


(3,028)


Payments for finance lease liabilities


(5,707)


(5,925)

Proceeds from employee stock purchase plan and stock option exercises


3,770


4,223

Tax withholdings on stock-based awards


(6,289)


(8,650)

Proceeds from issuance of common stock 


2,500


      Net cash used in financing activities


(8,754)


(85,352)






Net decrease in cash, cash equivalents and restricted cash


45,016


(77,078)

Cash, cash equivalents and restricted cash at beginning of period


136,649


213,727

Cash, cash equivalents and restricted cash at end of period


$    181,665


$    136,649

NON-GAAP FINANCIAL MEASURES

The following information provides definitions and reconciliations of the non-GAAP financial measures presented in this earnings release to the most directly comparable financial measures calculated and presented in accordance with generally accepted accounting principles (GAAP). The company has provided this non-GAAP financial information, which is not calculated or presented in accordance with GAAP, as information supplemental and in addition to the financial measures presented in this earnings release that are calculated and presented in accordance with GAAP. Such non-GAAP financial measures should not be considered superior to, as a substitute for or alternative to, and should be considered in conjunction with, the GAAP financial measures presented in this earnings release. The non-GAAP financial measures in this earnings release may differ from similarly titled measures used by other companies.

The tables below reflect the calculation of Adjusted EBITDA as applicable, for the thirteen and fifty-two weeks ended February 1, 2025 compared to the fourteen and fifty-three weeks ended February 3, 2024, respectively.

Adjusted EBITDA 

Adjusted EBITDA is considered a non-GAAP financial measure  under the Securities and Exchange Commission's (SEC) rules because it excludes certain amounts included in net income calculated in accordance with GAAP. Management believes that Adjusted EBITDA is a meaningful measure to share with investors because it facilitates comparison of the current period performance with that of the comparable prior period. In addition, Adjusted EBITDA affords investors a view of what management considers to be Petco's core operating performance as well as the ability to make a more informed assessment of such operating performance as compared with that of the prior period. Please see the company's Annual Report on Form 10-K for the fiscal year ended February 3, 2024 filed with the SEC on April 3, 2024 for additional information on Adjusted EBITDA.

(dollars in thousands)


13 Weeks
Ended


14 Weeks
Ended


52 Weeks
Ended


53 Weeks
Ended

Reconciliation of Net Loss Attributable to Class A and B-1
   Common Stockholders to Adjusted EBITDA


February 1,
2025


February 3,
2024


February 1,
2025


February 3,
2024

Net loss attributable to Class A and B-1 common stockholders


$       (13,837)


$       (22,575)


$        (101,816)


$   (1,280,210)

Add (deduct):









Interest expense, net


32,833


39,332


139,817


147,504

Income tax expense (benefit) 


2,504


(10,435)


(7,481)


(27,613)

Depreciation and amortization


50,313


52,189


199,727


200,782

Income from equity method investees


(5,112)


(6,156)


(18,669)


(16,188)

Loss on debt extinguishment and modification





920

Goodwill impairment





1,222,524

Losses on sale of assets, impairments and write-offs


341


631


8,790


2,833

Equity-based compensation expense


9,507


17,428


50,212


81,859

Other non-operating loss (income)


1,000



(4,800)


(4,727)

Mexico joint venture EBITDA (1)


11,233


11,759


41,615


38,226

Acquisition and divestiture-related integration costs (2)




3,719


Other costs (3)


7,341


23,167


25,412


35,193

Adjusted EBITDA


$       96,123


$     105,340


$        336,526


$      401,103

Net sales


$  1,552,130


$  1,674,476


$     6,116,462


$   6,255,284

Net margin (4)


(0.9 %)


(1.3 %)


(1.7 %)


(20.5 %)

Adjusted EBITDA Margin


6.2 %


6.3 %


5.5 %


6.4 %

Free Cash Flow

Free Cash Flow is a non-GAAP financial measure that is calculated as net cash provided by operating activities less cash paid for fixed assets. Management believes that Free Cash Flow, which measures the ability to generate additional cash from business operations, is an important financial measure for use in evaluating the company's financial performance.

The table below reflects the calculation of Free Cash Flow for the fifty-two weeks ended February 1, 2025 compared to the fifty-three weeks ended February 3, 2024.

(in thousands)


52 Weeks
Ended


53 Weeks
Ended



February 1,
2025


February 3,
2024

Net cash provided by operating activities


$    177,673


$    215,719

Cash paid for fixed assets


(127,990)


(225,598)

Free Cash Flow


$      49,683


$       (9,879)

Non-GAAP Financial Measures Footnotes

(1)

Mexico Joint Venture EBITDA represents 50 percent of the entity's operating results for all periods, as adjusted to reflect the results on a basis comparable to Adjusted EBITDA. In the financial statements, this joint venture is accounted for as an equity method investment and reported net of depreciation and income taxes because such a presentation would not reflect the adjustments made in the calculation of Adjusted EBITDA, we include the 50 percent interest in the company's Mexico joint venture on an Adjusted EBITDA basis to ensure consistency. The table below presents a reconciliation of Mexico joint venture net income to Mexico joint venture EBITDA.

 



13 Weeks
Ended


14 Weeks
Ended


52 Weeks
Ended


53 Weeks
Ended

(in thousands)


February 1,
2025


February 3,
2024


February 1,
2025


February 3,
2024

Net income


$      10,224


$      12,311


$      37,559


$      32,375

Depreciation


6,536


7,070


27,360


26,141

Income tax expense


5,014


2,541


16,010


11,449

Foreign currency loss


176


557


169


1,520

Interest expense, net


516


1,039


2,131


4,966

EBITDA


$      22,466


$      23,518


$      83,229


$      76,451

50% of EBITDA


$      11,233


$      11,759


$      41,615


$      38,226

 



(2)

Acquisition and divestiture-related integration costs include direct costs resulting from acquiring, integrating, or divesting businesses. These include third-party professional and legal fees, losses on sales of divestitures, and other integration-related costs that would not have otherwise been incurred as part of the company's operations.



(3)

Other costs include, as incurred: restructuring costs and restructuring-related severance costs; legal reserves associated with significant, non-ordinary course legal or regulatory matters; and costs related to certain significant strategic transactions.



(4)

We define net margin as net loss attributable to Class A and B-1 common stockholders divided by net sales and Adjusted EBITDA margin as Adjusted EBITDA divided by net sales.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/petco-health--wellness-company-inc-reports-fourth-quarter-and-full-year-2024-financial-results-302412288.html

SOURCE Petco - Investor Relations

In eigener Sache

Übrigens: Petco Health and Wellness Company A und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Petco Health and Wellness Company A

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Petco Health and Wellness Company A

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Petco Health and Wellness Company Inc Registered Shs -A-

Wer­bung